CORONA Remedies Reports Strong H1 FY27 Performance Driven by Chronic Segment Outperformance
Corona Remedies Ltd 路 Investor Presentation 路 31 Oct 2026, 2:13 am
CORONA Remedies Reports Strong H1 FY27 Performance Driven by Chronic Segment Outperformance CORONA Remedies reported revenue of INR 863.6 Cr (+22.0% YoY), EBITDA of INR 189.1 Cr (+27.5% YoY, margin 21.9%), and PAT of INR 120.4 Cr (+22.2% YoY) for H1 FY27, with annualized ROCE at 49.8% and ROE at 32.9%. Q2 FY27 revenue grew 22.2% YoY to INR 441.2 Cr. Chronic and sub-chronic therapies contributed ~72.1% of H1 FY27 revenue, while India accounted for 97.1%. The company secured ANVISA GMP certification for its Bhayla OSD and hormone facility in Oct'26.
Original exchange filing (PDF)
More announcements from Corona Remedies Ltd
- Intimation of Participation in Analyst / Investor Conference 路 16 Nov 2026
- Intimation of Participation in Analyst / Investor Conference 路 07 Nov 2026
- Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the second quarter and half year ended September 30, 2026 路 05 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 路 04 Nov 2026
- Audio Recording of Q2H1FY27 Earnings Conference Call with Analysts / Investors 路 02 Nov 2026
- Intimation for Analyst / Investor Meet 路 31 Oct 2026
- Press Release on Financial Results for second quarter and half year ended on September 30, 2026 路 31 Oct 2026
- Unaudited Financial Results along with the Limited Review Reports for the second quarter and half year ended September 30, 2026 路 31 Oct 2026
